Evidence map›Paper›PMID 23145056›Full record

ArticlePloS one2012

Structures of SHV-1 β-lactamase with penem and penam sulfone inhibitors that form cyclic intermediates stabilized by carbonyl conjugation.

Wei Ke, Priyaranjan Pattanaik, Christopher R Bethel, Anjaneyulu Sheri, John D Buynak, Robert A Bonomo, Focco van den Akker

Abstract read
In one paragraph

Article in PloS one, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Review
  3. Inhibition of theACS infectious diseases · 2021
    Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Wei KeDepartment of Biochemistry, Case Western Reserve University, Cleveland, OH, USA.
Priyaranjan Pattanaik
Christopher R Bethel
Anjaneyulu Sheri
John D Buynak
Robert A Bonomo
Focco van den Akker

Funding

Understanding ceftazidime resistance in SHV B-LactamasesR01AI063517 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI BONOMO, ROBERT A. · 2005 to 2023
$4.9M
Mechanistic studies and inhibition strategies for antibiotic resistanceR01AI062968 · NIAID · CASE WESTERN RESERVE UNIVERSITY · PI VAN DEN AKKER, FOCCO · 2007 to 2010
$1.1M
NIAID NIH HHS R01 AI062968NIAID NIH HHS R01 AI063517
6 · The paper itself

Abstract

Bacterial β-lactamase enzymes are in large part responsible for the decreased ability of β-lactam antibiotics to combat infections. The inability to overcome β-lactamase mediated resistance spurred the development of inhibitors with penems and penam sulfones being amongst the most potent and broad spectrum mechanism-based inactivators. These inhibitors form covalent, "suicide-type" inhibitory intermediates that are attached to the catalytic S70 residue. To further probe the details of the mechanism of β-lactamase inhibition by these novel compounds, we determined the crystal structures of SHV-1 bound with penem 1, and penam sulfones SA1-204 and SA3-53. Comparison with each other and with previously determined crystal structures of members of these classes of inhibitors suggests that the final conformation of the covalent adduct can vary greatly amongst the complex structures. In contrast, a common theme of carbonyl conjugation as a mechanism to avoid deacylation emerges despite that the penem and penam sulfone inhibitors form different types of intermediates. The detailed insights gained from this study could be used to further improve new mechanism-based inhibitors of these common class A serine β-lactamases.

Indexed as

beta-Lactamase Inhibitorsbeta-LactamasesCatalytic DomainCrystallography, X-RayKineticsMeropenemMolecular ConformationStructure-Activity RelationshipSulfonesThienamycinsbeta-Lactamase Inhibitorsbeta-lactamase PIT-2beta-LactamasesMeropenemSulfonesThienamycins

Identifiers

PMID23145056
PMCPMC3493512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.